Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: Difference in chiral preference of CYP2C9 and CYP2C19

Biochemical Pharmacology

Volumn 57, Issue 11, 1999, Pages 1297-1303

  Yasumori, Toshio ^a   Chen, Lai shun ^a   Li, Qing hua ^a   Ueda, Masakazu ^a   Tsuzuki, Toshiharu ^a   Goldstein, Joyce A ^b   Kato, Ryuichi ^a   Yamazoe, Yasushi ^c  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

Cytochrome P450; Drug metabolism; Expression in yeast; Human liver; Pharmacogenetics; Phenytoin; Polymorphism

Indexed keywords

CYTOCHROME C2; MEPHENYTOIN; PHENYTOIN;

ARTICLE; CHIRALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; LIVER MICROSOME; PHARMACOGENETICS; PRIORITY JOURNAL; SACCHAROMYCES; STEREOCHEMISTRY;

ANTIBODIES; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROXYLATION; JAPAN; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; PHENYTOIN; SACCHAROMYCES CEREVISIAE; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SUBSTRATE SPECIFICITY;

EID: 0033151546     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00034-9     Document Type: Article

References (35)

1. Meyer U.A., Zanger U.M., Grant D., Blum M. Genetic polymorphisms of drug metabolism. Adv Drug Res. 19:1990;197-241.
2. Butler T.C., Dudley K.H., Johnson D., Roberts S.B. Studies of the metabolism of 5,5-diphenylhydantoin relating principally to the stereoselectivity of the hydroxylation reactions in man and the dog. J Pharmacol Exp Ther. 199:1976;82-92.
3. Cavalier R., Toussaint A. Study in vivo of the stereoselective aromatic hydroxylation of diphenylhydantoin by man, rat and dog by the use of a specifically deuterated substrate. Arch Int Physiol Biochim. 86:1978;409-411.
4. Vasko M.R., Bell R.D., Daly D.D., Pippenger C.E. Inheritance of phenytoin hypometabolism A kinetic study of one family . Clin Pharmacol Ther. 27:1980;96-103.
5. Maguire J.H., Butler T.C., Dudley K.H. Absolute configurations of the dihydrodiol metabolites of 5,5-diphenylhydantoin (phenytoin) from rat, dog and human urine. Drug Metab Dispos. 8:1980;325-331.
6. Küpfer A., Preisig R. Pharmacogenetics of mephenytoin A new drug hydroxylation polymorphism in man . Eur J Clin Pharmacol. 26:1984;753-759.
7. Inaba T., Jurima M., Nakano M., Kalow W. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians. Clin Pharmacol Ther. 36:1984;670-676.
8. Wedlund P.J., Aslanian W.S., McAllister C.B., Wilkinson G.R., Branch R.A. Mephenytoin hydroxylation deficiency in Caucasians Frequency of a new oxidative drug metabolism polymorphism . Clin Pharmacol Ther. 36:1984;773-780.
9. Fritz S., Linder W., Roots I., Frey B.M., Küpfer A. Stereochemistry of aromatic phenytoin hydroxylation in various drug hydroxylation phenotypes in humans. J Pharmacol Exp Ther. 241:1987;615-622.
10. Schellens J.H.M., van der Wart J.H.F., Breimer D.D. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects. Br J Clin Pharmacol. 29:1990;665-671.
11. Ieiri I., Mamiya K., Urae A., Wada Y., Kimura M., Irie S., Amamoto T., Kubota T., Yoshioka S., Nakamura K., Nakano S., Tashiro N., Higuchi S. Stereoselective 4′-hydroxylation of phenytoin Relationship to (S)-mephenytoin polymorphism in Japanese . Br J Clin Pharmacol. 43:1997;441-445.
12. Nakamura K., Goto F., Ray W.A., McAllister C.B., Jacqz E., Wilkinson G.R., Branch R.A. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther. 38:1985;402-408.
13. Jurima M., Inaba T., Kadar D., Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation Difference between Orientals and Caucasians . Br J Clin Pharmacol. 19:1985;483-487.
14. Doecke C.J., Veronese M.E., Pond S.M., Miners J.O., Birkett D.J., Sansom L.N., McManus M.E. Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol. 31:1991;125-130.
15. Veronese M.E., Mackenzie P.I., Doecke C.J., McManus M.E., Miners J.O., Birkett D.J. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun. 175:1991;1112-1118.
16. Yasumori T., Nagata K., Yang S.K., Chen L., Murayama N., Yamazoe Y., Kato R. Cytochrome P450 catalyzing the metabolism of diazepam in human and rat Different forms are involved in the metabolic pathway- and substrate concentration-dependent manners . Pharmacogenetics. 3:1993;302-311.
17. m diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4′-hydroxylation. Pharmacogentics. 4:1994;323-331.
18. Yasumori T., Kawano S., Nagata K., Shimada M., Yamazoe Y., Kato R. Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. J Biochem. 102:1987;1075-1082.
19. Yasumori T., Murayama N., Yamazoe Y., Abe A., Nogi Y., Fukasawa T., Kato R. Expression of a human P-450IIC gene in yeast cells using galactose-inducible expression system. Mol Pharmacol. 35:1989;443-449.
20. Goldstein J.A., Faletto M.B., Romkes-Sparks M., Sullivan T., Raucy J.L., Kitareewan S., Lasker J.M., Ghanayem B. Evidence for a role for 2C19 in metabolism of S-mephenytoin in humans. Biochemistry. 33:1994;1743-1752.
21. de Morais S.M.F., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A. The major defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 269:1994;15419-15422.
22. Yasumori T., Murayama N., Yamazoe Y., Kato R. Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers in relation to hepatic P-450 human-2. Clin Pharmacol Ther. 47:1990;313-322.
23. Meier U.T., Dayer P., Malè P.J., Kronbach T., Meyer U.A. Mephenytoin hydroxylation polymorphism Characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo . Clin Pharmacol Ther. 38:1985;488-494.
24. Yasumori T. Expression of a human cytochrome P450 form in Schizosaccharomyces pombe Comparison with expression in Saccharomyces cerevisiae . Giga-Hama Y., Kumagai H., Foreign Gene Expression in Fission Yeast Schizosaccharomyces pombe. 1997;111-121 Springer-Verlag, Berlin Heidelberg.
25. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem. 193:1951;265-275.
26. Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem. 239:1964;2370-2378.
27. Folch J., Lees M., Stanley G.H.S. A simple method for the isolation and purification of total lipids from animal tissue. J Biol Chem. 226:1957;497-509.
28. Kawano S., Kamataki T., Yasumori T., Yamazoe Y., Kato R. Purification of human liver cytochrome P-450 catalyzing testosterone 6β-hydroxylation. J Biochem. 102:1987;493-501.
29. Krecic M.E., Shepard D.R., Chang T.-H., Collins J., Gerber N. Stereoselective metabolism of phenytoin by hepatic microsomes and human 2C9 and 2C18 expressed in yeast. ISSX Proc. 8:1995;370.
30. Knodell R.G., Hall S.D., Wilkinson G.R., Guengerich F.P. Hepatic metabolism of tolbutamide Characterization of the form of cytochrome P450 involved in methyl hydroxylation and relationship to in vivo disposition . J Pharmacol Exp Ther. 241:1987;1112-1119.
31. Andersson T., Miners J.O., Veronese M.E., Tassaneeyakul W., Tassaneeyakul W., Meyer U.A., Birkett D.J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol. 36:1993;521-531.
32. Chiba K., Kobayashi K., Manabe K., Tani M., Kamataki T., Ishizaki T. Oxidative metabolism of omeprazole in human liver microsomes Cosegregation with S-mephenytoin 4′-hydroxylation . J Pharmacol Exp Ther. 266:1993;52-59.
33. Bajpai M., Roskos L.K., Shen D.D., Levy R.H. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos. 24:1996;1401-1403.
34. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 6:1996;341-349.
35. Veronese M.E., Doecke C.J., Mackenzie P.I., McManus M.E., Miners J.O., Rees D.L.P., Gasser R., Meyer U.A., Birkett D.J. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J. 289:1993;533-538.